
AstraZeneca and Daiichi Sankyo said the EU approved Enhertu as a single treatment after surgery for patients with residual HER2-positive disease.
The European Commission has approved AstraZeneca and Daiichi Sankyo’s Enhertu for certain patients with early-stage HER2-positive breast cancer. The treatment is for patients who have residual disease after surgery and will be used as a monotherapy.
The companies said the EU approval followed a recommendation from the European Medicines Agency’s scientific committee. They described it as Enhertu’s first EU approval for early breast cancer with curative intent.
The decision was based on late-stage clinical trial data that showed the drug reduced the risk of disease recurrence or death, according to the companies.
AstraZeneca shares traded at 12,822 GBp on Tuesday afternoon, down 0.25% since the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.